Universitätsklinikum Halle (Saale) Universitätsklinik und Poliklinik für Gynäkologie
Welcome,         Profile    Billing    Logout  
 3 Trials 
3 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Thomssen, Christoph
ADAPTlate, NCT04565054 / 2019-001488-60: Adjuvant Therapy With Abemaciclib + SOC ET vs. SOC ET in Clinical or Genomic High Risk, HR+/HER2- EBC

Recruiting
3
1260
Europe
Abemaciclib 50 MG; 150mg 1-0-1 per os, Verzenios
West German Study Group, Eli Lilly and Company, Genomic Health®, Inc.
Breast Cancer Female
08/26
03/28
SASCIA, NCT04595565 / 2019-004100-35: Sacituzumab Govitecan in Primary HER2-negative Breast Cancer

Active, not recruiting
3
1332
Europe
Capecitabine, Xeloda, Carboplatin, Paraplatin, Cisplatin, Platinol, Sacituzumab govitecan, Trodelvy
German Breast Group, Gilead Sciences, Austrian Breast & Colorectal Cancer Study Group, Spanish Breast Cancer Research Group (GEICAM), ETOP IBCSG Partners Foundation, Cancer Trials Ireland, UNICANCER
HER2-negative Breast Cancer, Triple Negative Breast Cancer
03/27
03/29
ADAPTcycle, NCT04055493: Adj. Marker-adjusted Personalized Therapy Comparing ET+Ribociclib vs Chemotherapy in Intermediate Risk, HR+/HER2- EBC

Active, not recruiting
3
1684
Europe
Ribociclib 200Mg Oral Tablet, Kisqali
West German Study Group, Novartis, Genomic Health®, Inc.
Breast Cancer Female
07/27
07/27

Download Options